Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Paffett, Michael L ^a   Hesterman, Jacob ^b   Candelaria, Gabriel ^c   Lucas, Selita ^a   Anderson, Tamara ^c   Irwin, Daniel ^c   Hoppin, Jack ^b   Norenberg, Jeffrey ^c   Campen, Matthew J ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b inviCRO   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 5; RESVERATROL; TECHNETIUM 99M; THALLIUM 201;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART PERFUSION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; IN VIVO STUDY; LUNG EDEMA; NONHUMAN; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANNEXINS; APOPTOSIS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MONOCROTALINE; MYOCARDIUM; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; SYSTOLE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VENTRICULAR REMODELING;

ANIMALIA; RATTUS; RODENTIA;

EID: 84864002608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040910     Document Type: Article

References (24)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 43: 13S-24S.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brudage BH, et al. (1991) Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115: 343-349.
3. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, et al. (2006) National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114: 1883-91.
4. Marsboom G, Wieholt C, Haney CR, Toth PT, Ryan JJ, et al. (2012) Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med. 185: 670-9.
5. Campian ME, Verberne HJ, Hardziyenka M, de Bruin K, Selwaness M, et al. (2009) Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J Nucl Med. 50: 1371-7.
6. Paffett ML, Lucas SL, Campen MJ, (2012) Resveratrol Reverses Monocrotaline-Induced Pulmonary Vascular and Cardiac Dysfunction: A Potential Role for Atrogin-1 in Smooth Muscle. Vascular Pharmacology 56: 64-73.
7. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, et al. (2009) Resveratrol Prevents Monocrotaline-Induced Pulmonary Hypertension in Rats. Hypertension 54: 668-675.
8. Jian B, Yang S, Chaudry IH, Raju R, (2011) Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating SIRT1. Mol Med. 18: 209-14.
9. Louis XL, Thandapilly SJ, Mohankumar SK, Yu L, Taylor CG, et al. (2011) Treatment with low-dose resveratrol reverses cardiac imparment in obese prone but not obese resistant rats. J Nutr Biochem. http://dx.doi.org/10.1016/j.jnutbio.2011.06.010 [Epub ahead of print].
10. Zhang C, Feng Y, Qu S, Wei X, Zhu H, et al. (2011) Resveratrol attenuates doxorubicin-induced cardiomyocytes apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res. 90: 538-45.
11. Rimbaud S, Ruiz M, Piquereau J, Mateo P, Fortin D, et al. (2011) Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PloS ONE. 6: 1-12.
12. Chen YR, Yi FF, Li XY, Wang CY, Chen L, et al. (2008) Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther. 22: 479-485.
13. Santamore WP, Dell'Italia LJ, (1998) Ventricular interdependence: significant left ventricular contributions to right ventricular function. Prog Cardiovasc Dis. 40: 289-308.
14. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP, (1998) Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 113: 576-83.
15. Correia-Pinto J, Henriques-Coelho T, Roncon-Albuquerque R Jr, Lourenco AP, Melo-Rocha G, et al. (2009) Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotaline-induced pulmonary hypertension. Basic Res Cardiol. 104: 535-45.
16. Morrell NW, Higham MA, Phillips PG, Shakur BH, Robinson PJ, et al. (2005) Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res. 6: 88.
17. Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, et al. (2006) The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol. 373: 401-14.
18. Zaiman AL, Podowski M, Medicherla S, GordyK, Xu F, et al. (2008) Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med. 177: 896-905.
19. Yang DL, Zhang HG, Xu YL, Gao YH, Yang XJ, et al. (2010) Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin Exp Pharmacol Physiol. 37: 150-155.
20. Lamberts RR, Caldenhoven E, Lansink M, Witte G, Vaessen RJ, et al. (2007) Preservation of diastolic function in monocrotaline-induced right ventricular hypertrophy in rats. Am J Physiol Heart Circ Physiol. 293: H1869-76.
21. Chan V, Fenning A, Iyer A, Hoey A, Brown L, (2011) Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol. 12: 429-36.
22. Price LC, Montani D, Tcherakian C, Dorfmuller P, Souza R, et al. (2011) Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J. 37: 813-22.
23. Wang W, Wang YL, Chen XY, Li YT, Hao W, et al. (2011) Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep. 38: 3277-84.
24. Laufer EM, Reutelingsperger CPM, Narula J, Hofstra L, (2008) Annexin V: an imaging biomarker of cardiovascular risk. Basic Res Cardiol. 103: 95-14.